Connor, Clark & Lunn Investment Management Ltd. Eye Point Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 48,791 shares of EYPT stock, worth $391,303. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,791
Previous 120,587
59.54%
Holding current value
$391,303
Previous $1.05 Million
62.92%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding EYPT
# of Institutions
150Shares Held
58MCall Options Held
177KPut Options Held
263K-
Cormorant Asset Management, LP Boston, MA8.33MShares$66.8 Million4.66% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$41.5 Million1.63% of portfolio
-
Franklin Resources Inc San Mateo, CA4.01MShares$32.2 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.79MShares$30.4 Million0.06% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$30.2 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $273M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...